Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 1.00 |
| ▸ | IDO1 | P14902 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CES2 | O00748 | 2/20 | 1.00 |
| ▸ | TDP2 | O95551 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CES1 | P23141 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapachone SCHEMBL29351050 | 1.00 | MALT1 (1.00) | MALT1IDO1LMNAKDM4EMEN1 | |
| Alpha-Lapachone SCHEMBL102553 | 0.89 | IDO1 (1.00) | MALT1IDO1LMNAKDM4EMEN1 | |
| Alpha-Lapachone SCHEMBL29355317 | 0.89 | IDO1 (1.00) | MALT1IDO1LMNAKDM4EMEN1 | |
| SCHEMBL15034364 | 0.86 | MALT1 (0.76) | MALT1IDO1LMNAKDM4EMEN1 | |
| SCHEMBL8186444 | 0.86 | MALT1 (0.76) | MALT1IDO1LMNAKDM4EMEN1 | |
| SCHEMBL10916022 | 0.84 | MALT1 (0.72) | MALT1IDO1LMNAKDM4EMEN1 | |
| SCHEMBL10916020 | 0.84 | MALT1 (0.72) | MALT1IDO1LMNAKDM4EMEN1 | |
| Nor-Beta-Lapachone SCHEMBL107599 | 0.83 | MALT1 (0.71) | MALT1IDO1LMNAKDM4EMEN1 | |
| SCHEMBL5940435 | 0.83 | MALT1 (0.75) | MALT1IDO1LMNAKDM4EMEN1 | |
| SCHEMBL18774141 | 0.83 | MALT1 (0.70) | MALT1IDO1LMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025030135-A2 | METHODS FOR TREATING AND AMELIORATING ANGINA, MYOCARDIAL INFARCTION, REPERFUSION INJURY, HEART ARRHYTHMIAS AND CONGESTIVE HEART FAILURE (CHF) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-06 | — | — | WO | claimed |
| US-20160361288-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DIABETIC NEPHROPATHY COMPRISING THE ACTIVITY INHIBITOR OF TENC1 | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2016-12-15 | — | — | US | claimed |
| EP-2426212-A1 | Method for controlling NAD(P)/NAD(P)H ratio by oxidoreductase | Md Bioalpha Co., Ltd. (KR) | 2012-03-07 | — | — | EP | claimed |
| US-20090215145-A1 | METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE | MD BIOALPHA CO., LTD. (KR) | 2009-08-27 | — | — | US | claimed |
| EP-4651865-A2 | COMBINATION THERAPY FOR CANCER USING ROS-ACTIVATED PRODRUGS AND ROS-AMPLIFYING THERAPEUTICS | UWM Research Foundation, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250319110-A1 | SURFACE CALR CHEMICAL INDUCERS | ZON LEONARD (US) | 2025-10-16 | — | — | US | disclosed |
| US-12370170-B2 | Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment | NADIANBIO LTD. (KR) | 2025-07-29 | — | — | US | disclosed |
| EP-3449920-B1 | COMPOSITION COMPRISING DUNNIONE OR BETA-LAPACHONE AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | NADIANBIO LTD (KR) | 2025-05-28 | — | — | EP | disclosed |
| EP-4540374-A1 | SURFACE CALR CHEMICAL INDUCERS | The Children's Medical Center Corporation (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025030135-A2 | METHODS FOR TREATING AND AMELIORATING ANGINA, MYOCARDIAL INFARCTION, REPERFUSION INJURY, HEART ARRHYTHMIAS AND CONGESTIVE HEART FAILURE (CHF) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-06 | — | — | WO | disclosed |
| CN-113679726-B | Application of red sage root extract and quinone compound in resisting coronavirus | 上海科技大学 | 2025-01-10 | — | — | CN | disclosed |
| CN-119144686-A | Intracellular redox probe-based antitumor drug metabolism evaluation and screening method | 华东理工大学 | 2024-12-17 | — | — | CN | disclosed |
| WO-2003011224-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING BETA-LAPACHONE, OR DERIVATIVES OR ANALOGS THEREOF, AND METHODS OF USING SAME | ARQULE, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002059103-A9 | SYNTHESIS OF BETA-LAPACHONE AND ITS INTERMEDIATES | CYCLIS PHARMACEUTICALS INC (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020169135-A1 | Method of treating hematologic tumors and cancers | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2002-11-14 | — | — | US | disclosed |
| US-6458974-B1 | Synthesis of β-lapachone and its intermediates | CYCLIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020137952-A1 | SYNTHESIS OF BETA-LAPACHONE AND ITS INTERMEDIATES | ARQULE, INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002059103-A1 | SYNTHESIS OF BETA-LAPACHONE AND ITS INTERMEDIATES | CYCLIS PHARMACEUTICALS, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058694-A2 | METHOD OF TREATING HEMATOLOGIC TUMORS AND CANCERS USING BETA LAPACHONE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0183649-A1 | Nitrogen derivatives from oxo compounds | CIBA-GEIGY AG (CH) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370170-B2 | Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment | ACHE, NES, GSTO1 | MALT1 3000/4885IDO1 3195/4885LMNA 735/4885 |
| US-20020169135-A1 | Method of treating hematologic tumors and cancers | MCL1, CCNE1, CCNB1 | MALT1 70/4885IDO1 2996/4885LMNA 37/4885 |
| US-20090215145-A1 | METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE | NQO1, NADK, ME2 | MALT1 4170/4885IDO1 1756/4885LMNA 1441/4885 |
| US-20020137952-A1 | SYNTHESIS OF BETA-LAPACHONE AND ITS INTERMEDIATES | LSS, SQLE, HCCS | MALT1 2778/4885IDO1 3221/4885LMNA 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.